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SUMMARY
The decoration of proteins by carbohydrates is
essential for eukaryotic life yet heterogeneous due
to a lack of biosynthetic templates. This complex car-
bohydrate mixture—the glycan profile—is generated
in the compartmentalized Golgi, in which level and
localization of glycosylation enzymes are key deter-
minants. Here, we develop and validate a computa-
tional model for glycan biosynthesis to probe how
the biosynthetic machinery creates different glycan
profiles. We combined stochastic modeling with
Bayesian fitting that enables rigorous comparison
to experimental data despite starting with uncertain
initial parameters. This is an important development
in the field of glycan modeling, which revealed bio-
logical insights about the glycosylation machinery
in altered cellular states.We experimentally validated
changes in N-linked glycan-modifying enzymes in
cells with perturbed intra-Golgi-enzyme sorting and
the predicted glycan-branching activity during os-
teogenesis. Our model can provide detailed informa-
tion on altered biosynthetic paths, with potential for
advancing treatments for glycosylation-related dis-
eases and glyco-engineering of cells.
INTRODUCTION
Glycosylation is a ubiquitous post-translationalmodification in eu-
karyotes. It plays roles ranging fromprotein stability (Waetzig etal.,
2010) through cell adhesion (Zhao et al., 2008) to complex physi-
ological traits like antibody-dependent cellular cytotoxicity (Fer-
rara et al., 2006;Shields et al., 2002).N-linkedglycosylation is initi-
ated in the endoplasmic reticulum (ER), with subsequent glycan
processing during transport through the Golgi. Within the Golgi,
an interplay of glycosidase-mediated mannose trimming and
monosaccharide additions via glycosyltransferases (Figure 1A)
generates N-glycans classed as oligomannose (five to nine man-
noses), hybrid (at least one N-acetylglucosamine [GlcNAc]-initi-
ated antenna and five mannoses), and complex (up to five
GlcNAc-seeded antennae). The GlcNAc-seeded antennae in
complex glycans can be extended through galactosylation and
capped by the often-functional sialic acid (Christie et al., 2008;
Scott and Panin, 2014). Another functionally important modifica-
tion is fucosylation,whichcanoccuron thechain-initiatingGlcNAc
(core fucosylation) or the antennae (Hemmerich et al., 1994). In the
absence of a template, and due to the limited time spent in the
Golgi, competition among enzymatic modifications generates a
heterogeneous glycan mixture (Stanley and Sudo, 1981).
Glycosylation enzymes are non-uniformly distributed between
Golgi cisternae (Dunphy and Rothman, 1983; Rabouille et al.,
1995). The levels and distributions of enzymes are cell type spe-
cific, and together they determine a given cell’s glycan profile
(Fisher and Ungar, 2016). Enzyme distributions are maintained
through sorting via COPI-coated retrograde vesicles (Harris
andWaters, 1996) that must be correctly targeted to the relevant
cisterna or cisternae. The conserved oligomeric Golgi (COG)
complex is involved in COPI-vesicle targeting at the Golgi appa-
ratus through its ability to self-assemble (Willett et al., 2016) and
interact with other trafficking proteins (Fukuda et al., 2008; Miller
et al., 2013; Willett et al., 2013). COG defects have been shown
to result in aberrant glycosylation in model systems (Abdul Rah-
man et al., 2014; Bailey Blackburn et al., 2016; Belloni et al.,
2012; Pokrovskaya et al., 2011; Struwe and Reinhold, 2012;
Whyte and Munro, 2001) and in an expanding group of genetic
disorders known as congenital disorders of glycosylation
(CDGs) (Kodera et al., 2015; Zeevaert et al., 2008).
Mesenchymal stromal cells (MSCs) are a valuable model for
studying glycan function. They can differentiate into several
cell types, and the Y101 immortalized human MSC line readily
differentiates into osteoblasts under suitable growth conditions
(James et al., 2015). The glycan profile of Y101-derived osteo-
blasts is markedly different from that of the parent MSC lines
(Wilson et al., 2016). Glycosylation has been shown to modulate
the ability of thisMSC line to undergo osteogenesis (Wilson et al.,
2018). Specifically, inhibition of mannosidase I (MAN1), which
limits N-glycans to their oligomannose form, increases differen-
tiation. Yet it is unclear which glycan structures are modulating
differentiation (Wilson et al., 2018).
Established kinetic models of glycosylation, based on ordinary
differential equations (ODEs) (Krambeck and Betenbaugh, 2005;
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Krambeck et al., 2009; Uman˜a and Bailey, 1997), assume that
the essential dynamics of glycan biosynthesis are appropriately
captured by this deterministic approach. Other models based on
ODEs have explored the role of multiple compartments in glycan
biosynthesis (Hossler et al., 2007; Liu et al., 2008). For example,
Hossler et al. (2007) modeled glycosylation in the context of ve-
sicular transport and cisternal maturation of the Golgi apparatus
and concluded that cisternal maturationwasmore likely to be the
true mechanism, although it has been suggested that better
approximations regarding modeling of the cisternal maturation
process could have been made (Krambeck et al., 2017). These
models of glycosylation are based on ODEs; however, the signif-
icant heterogeneity in glycan structures suggests that stochastic
models (e.g., Spahn et al., 2016), explicitly incorporating molec-
Figure 1. Modeling N-Linked Glycosylation
in Mammalian Cells
(A) Example of the sequential nature of theN-linked
glycosylation pathway in mammalian cells. MAN1
trims oligomannose glycans before conversion to
the hybrid class through the action of MGAT1.
Before galactose is added to the complex branch
of the hybrid structure, the removal of two
mannose residues by MAN2 can convert hybrid
into complex glycans. Fucosylation on the
antennae of complex glycans (ant Fut) can be
catalyzed by several fucosyltransferases that are
grouped for the simulation of glycosylation re-
actions. The sialylation rate for the different
branches of bi-antennary glycans was modeled
separately to account for potentially different rates.
(B) Schematic representation of the stochastic
simulation algorithm (SSA) used to simulate
glycosylation reactions. The propensity for each
competing reaction is used to calculate the
probability of each reaction occurring. Time is
then advanced by dt, which is drawn from an
exponential distribution with a mean equal to
1=total propensity. An example of the linear nota-
tion used to define a glycan structure, which was
used for substrate recognition and modification
following a reaction by the modeling software, is
also included. Each monosaccharide residue is
defined, along with the link as a linear string.
Brackets represent separate branches, and colons
represent the terminus of each branch. These
strings can be recognized by enzyme rules in the
SSA. The conventional notations for the glycan
structures are shown for comparison.
See also Figure S1 and Table S1.
ular noise, may offer greater insight. This
has been recognized in other aspects of
biology (Eldar and Elowitz, 2010). Here
we report development of a stochastic
model of N-linked glycan processing
and use Bayesian fitting (Csille´ry et al.,
2010) to measured glycan profiles to pre-
dict changes in Golgi-enzyme organiza-
tion in three human model cell lines. In
our model, we started with the assump-
tion that the enzymatic rates are not sub-
strate specific, only enzyme specific, in contrast to ODEmodels.
Substrate specificity for a limited set of reactions was introduced
when required as typical of deterministic models. Our model
makes experimentally testable predictions about the altered
levels and localizations of enzymes in COG mutants and pro-
vides a testable hypothesis for the functional role of specific
glycans during cell differentiation.
RESULTS
Model Development
A cell’s highly heterogeneous N-glycan profile depends on the
levels, enzymatic rates, and distributions of individual enzymes
in the Golgi cisternae. We simulate the glycosylation reactions
1232 Cell Reports 27, 1231–1243, April 23, 2019
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using a stochastic simulation algorithm (SSA) (Figure 1B) (Gibson
and Bruck, 2000; Gillespie, 1976), in contrast to the differential
equation approach used previously (Krambeck andBetenbaugh,
2005; Krambeck et al., 2009). The SSA captures all possible re-
actions as discrete events, determined by a set of rules for each
enzyme (Table S1) that dictate which substrates it is converting
to which products. Each glycan is acted upon by a changing
set of enzymes constrained by their available target sites; as
new monosaccharides are added, acceptable target sites also
change (Figure 1B). These reactions happen at random times
and in a random order depending on the enzymatic rate and
amount of each enzyme but independent of how the glycan sub-
strate was generated.
The enzymatic reactions are implemented using string substi-
tutions to add or remove monosaccharides on the glycans
represented in a form of linear notation to build new structures
(Figure 1B). The linear notation is similar to those previously
used (Krambeck and Betenbaugh, 2005) and has been devel-
oped for computational convenience. All simulated glycan pro-
files are compared with experimental glycan profiles obtained
mass spectrometrically from permethylated glycans. The use
of MALDI mass spectrometry (MALDI-MS) of permethylated gly-
cans has been demonstrated and accepted to provide relative
quantification of glycans (Mehta et al., 2016; Orlando, 2010;
Wada et al., 2007). To generate a computational glycan profile
to be compared to experimental mass spectra, we simulate a
large number (n = 10,000) of input glycans entering the Golgi
one at a time. The glycans entering the simulated Golgi are
drawn from a distribution of structures known to exit the ER
(Man8, Man9, and Man9Glc). As the glycan is processed by the
SSA, it undergoes successive modifications until a time limit is
reached and it passes to a new cisterna.
To determine a set of appropriate rates for the SSA based on
the relative effective enzymatic rates of the glycan-modifying en-
zymes and their unique localizations within the Golgi stack, our
computational method is parameterized using a Bayesian frame-
work (Figure S1) (Marjoram et al., 2003). Throughout this work,
we have adopted the term ‘‘effective enzymatic rate’’ to describe
the composite nature of the parameter used in the modeling. We
define the effective enzymatic rate as the product of the en-
zyme’s protein level, the availability of its nucleotide-monosac-
charide substrate, and its inherent chemical enzymatic rate.
The effective enzymatic rate parameters are not direct measure-
ments of enzyme rate constants but rather a composite of
enzyme features. Only changes in these parameters are consid-
ered, not their absolute values; therefore, only relative, rather
than absolute, glycan quantification is required for the modeling.
The unique advantage of using a Bayesian framework is that it
allows us to incorporate existing knowledge, no matter how
tentative or precise, to construct a series of prior distributions
for our parameters. This results in a broad distribution for largely
unknown parameters or a sharp distribution centered around a
single value for well-characterized parameters. This allows us
to not require exact, well-defined enzymatic rates, protein levels,
and localizations.
We challenge this modeling framework by comparing its
output to experimental glycan profiles. This results in a fitting
process whereby our initial prior distributions are systematically
updated to give a new set of parameter distributions called pos-
teriors. The shift between the priors and the posteriors both re-
flects clarifications of our existing knowledge during initial fitting
and can capture real biological changes during empirical pertur-
bation between cellular states.
Our experimental glycan profiles were collected from whole-
cell lysates that contain a significant proportion of oligomannose
glycans. Significant sources of these may be endo-lysosomal
glycoproteins or recycled ER-resident proteins. Endo-lysosomal
glycoproteins are predominantly decorated with oligomannose
glycans due to the Man-6-phosphate (Man6P) targeting tag
that prevents conversion to hybrid and complex glycans (Bieber-
ich, 2014). ER-resident glycoproteins that are recycled from the
Golgi may also contain oligomannose glycans that do not
undergo further processing. Therefore, we included a parameter
(oligomannose [OM] quench) that prevents oligomannose
glycans from being further processed. The OM quench param-
eter is effectively a combination of the GlcNAc-1-phosphotrans-
ferase enzyme that initiatesMan6P biosynthesis and the removal
of ER glycoproteins from the Golgi via retrograde traffic to the
ER. Modeling started with rules covering the set of reactions
able to generate all possible glycans in a profile. To achieve
high-quality fits to experimental glycan profiles, rules (detailed
later) had to be refined and modified, justified by the existing
literature. These refinements represent internal properties of
the enzymes (e.g., substrate-specific rates) and were therefore
modeled as scale factors that alter the effective enzymatic rates
(Figure S2; Table S2).
Modeling N-Glycosylation in Mammalian Cell Lines
We first tested the model on the simple HeLa cell glycan profile
(>90% oligomannose) and the more complex HEK293T glycan
profile. The HeLa glycan profile could be reproduced in silico
with amodel distributing enzymes into three cisternae (Figure 2A;
Table S4), theminimumnumber of cisternae required.Minimizing
the cisterna number prevents excessive use of computational
Figure 2. Model Development for WT Mammalian Cell Lines
(A and B) Observed and simulated glycan profiles of whole-cell WTHeLa cells (A) and HEK293T cells (B). The glycan profile is simulated three times using the SSA,
with the mean parameter values from all individual fitting runs used to generate an average glycan profile with error bars. For glycan profiles, the error bars are
SEM for n = 3.
(C) Prior parameter distribution values for the MAN1 enzyme contrasted with posterior values following optimization of the MAN1 effective enzymatic rates.
Initially, MAN1 was modeled as a cis-Golgi enzyme.
(D) Predicted distributions of selected enzymes following fitting. Error bars are SD for n = 20 (HeLa) and n = 15 (HEK293T) individual fitting procedures.
(E) Airyscan confocal micrographs of GM130 and MAN1 or endo-mannosidase in nocodazole-treated WT HEK293T cells. Scale bar is 5 mm.
(F) Pearson’s correlation coefficients for GM130-MAN1 and GM130-endo-mannosidase. Pearson’s correlation coefficients were calculated for each Golgi stack,
and error bars are SD for n = 55 (MAN1) and n = 62 (endo-mannosidase) stacks. ***p < 0.001 for a Student’s t test.
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time. To fit the oligomannose glycan distribution, a scale factor
was necessary to modify the rate for converting Man6GlcNAc2
to Man5GlcNAc2 as published (Bause et al., 1992; Lal et al.,
1998); this was then used throughout the study (Figure S2;
Table S2).
Our initial assumption based on the literature was thatMAN1 is
predominately cis-Golgi localized (Dunphy and Rothman, 1983;
Marra et al., 2001). However, after fitting, the model predicted
it spread over the whole stack, with a weak medial-Golgi prefer-
ence (Figure 2C). Although often considered a cis-Golgi marker,
MAN1 localization has been shown to vary across cell types
(Velasco et al., 1993), consistent with our in silico finding.
Furthermore, confocal microscopy revealed that MAN1 localizes
adjacent to the cis-Golgi marker GM130 in HEK293T cells, in
contrast to Golgi-endo-mannosidase that colocalizes with this
marker (Figures 2E and 2F). This is consistent with our model’s
prediction that MAN1 is positioned away from the cis side and
thus closer to the medial Golgi than the endo-mannosidase in
the modeled cell lines (Table S4).
Fitting theHEK293Tglycan profiles started from the fittedHeLa
parameters, allowing comparison of the two cell lines. However,
for a good HEK293T profile fit, a fourth model cisterna was
required (Figure 2B; Table S5), likely due to this cell line’s more
complex glycan profile. Moreover, to achieve this fit, separate
rates for the sialylation of galactoses on the 3.1Man and 6.1Man
antennae (Barb et al., 2009; Joziasse et al., 1987), and galactosy-
Figure 3. Validation of Fitting Methodology
with Drug Treatment of Mammalian Cells
(A and B) Observed and simulated glycan profiles
of HeLa cells (A) and HEK293T cells (B) following
treatment with the MAN2 inhibitor swainsonine
(SW). Error bars for glycan profiles are SEM
for n = 3.
(C) Predicted total effective enzymatic rate of the
MAN2 enzyme in both cell lines with and without
swainsonine treatment normalized to the total
MAN2 effective enzymatic rate modeled in the
untreated cell lines.
(D) Prior and posterior distributions of the MAN2
effective enzymatic rate in the second cisterna of
HEK293T cells.
(E) Total effective enzymatic rate changes upon
swainsonine treatment for selected enzymes.
Error bars are SD for n = 13 (HeLa) and n = 16
(HEK293T) individual fitting procedures.
(F) Observed swainsonine-treated HEK293T
glycan profile and simulated glycan profile using
the parameters fitted for untreated cells but with
the MAN2 effective enzymatic rate set to 0.
See also Tables S4 and S5.
lation of bi- versus tri- and tetra-antennary
glycans (Ramasamy et al., 2005), had to
be introduced. These additions were pre-
sumably not required for fitting the HeLa
cell data, because they mainly affect
hybrid- and complex-type glycans, which
are in low abundance in HeLa cells. In
HEK293T cells, MAN1 is predicted to
have a predominantly early-medial localization (Figure 2D; Table
S5), in contrast to its medial location in HeLa cells, which is likely
a consequence of the additional cisterna introduced to process
more complex glycans.
To demonstrate that our model can make rational predictions,
we treated both HeLa and HEK293T cells with the mannosidase
II (MAN2) inhibitor swainsonine (Elbein et al., 1981). This results in
strongly increased hybrid N-glycan content and generation of
fucosylated Man5GlcNAc2. To allow for this fucosylation reac-
tion, albeit at a lower rate than with other substrates (Crispin
et al., 2006; Lin et al., 1994; Yang and Wang, 2016; Yang et al.,
2017), a scale factor was added for fucosyltransferase 8
(FUT8) modifying Man5GlcNAc2 (Figure S2; Table S2). Starting
with the parameter values obtained from fitting the glycan
profiles of untreated cells, we fitted to the glycan profiles of
swainsonine-treated HEK293T and HeLa cells by optimizing
parameter values within the established modeling framework
(Figures 3A and 3B). The model obtained predicts the expected
large decrease in the effective enzymatic rate of MAN2 (Figures
3C and 3D).
The model also predicts an unexpected increase in effective
sialylation rate in both cell lines (Figure 3E). The requirement
for increased sialylation was confirmed by simulating a glycan
profile using the original HEK293T parameters but with the
MAN2 enzyme removed to account for the known effect of
swainsonine. The resulting simulated profile only partially
Cell Reports 27, 1231–1243, April 23, 2019 1235
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matched the drug-treated experimental glycan profile (Fig-
ure 3F), demonstrating that the fitting procedure is required to
capture novel features in glycan processing.
Predicting the Impact of Trafficking Defects
Several conditions, such as CDGs, cancers, and cellular differ-
entiation, can alter the levels and localizations of glycosylation
enzymes. Experimentally determining such changes, in partic-
ular altered cisternal localization, is difficult, especially when
dealing with a dozen or more enzymes. Perturbing COG sub-
units alters cellular glycan profiles (Abdul Rahman et al., 2014;
Bailey Blackburn et al., 2016; Skeene et al., 2017). Therefore,
to test the model’s ability to predict changes in enzyme levels
and localizations, we fitted the glycan profiles of a Cog4 knock-
down (Cog4KD) HeLa cell line and a Cog4 knockout (Cog4KO)
HEK293T cell line, in each case starting with the fitted parameter
set for the respective wild-type (WT) profile. The altered relative
intensities of oligomannose-type glycans in Cog4KD HeLa cells
could be replicated in silico (Figure 4A). The alteration to the
oligomannose abundance leads our model to predict MAN1 dis-
tribution to flatten out and shift to a more trans-Golgi localization
(Figure 4E). Moreover, a reduction in the overall effective MAN1
rate is predicted by the model (Figure 4C).
The Cog4KD HeLa cell model focuses on oligomannose gly-
cans and their modifying enzymes. In contrast, the Cog4KO
HEK293T cells show marked changes in complex glycans:
they show large decreases in the levels of fucosylation and sia-
lylation, in addition to redistribution of oligomannose glycans
(Bailey Blackburn et al., 2016) without a significant change in
the cell surface proteome (Figure S6; Table S3). To simulate
the glycan profile of these cells (Figure 4B), the model predicts
decreases in the total effective enzymatic rates of N-acetylglu-
cosaminyltransferase I (MGAT1), N-acetylglucosaminyltransfer-
ase V (MGAT5), MAN2, and galactosyltransferase (GalT) (Fig-
ure 4C; Figure S3). We validated the predicted decreases in
GalT andMGAT1 levels throughwestern blotting (Figure 4D). Un-
expectedly, the model predicts the effective enzymatic rate of
FUT8 to show no significant change upon Cog4KO, despite
the observed reduction in overall fucosylation levels (Bailey
Blackburn et al., 2016), a prediction also validated by western
blotting (Figure 4D).
Upon fitting the Cog4KO HEK293T profile, three enzymes ex-
hibited localization changes compared with WT (Figure 4F). The
distribution of MAN1 was shifted in the trans direction, although
to a smaller degree compared to Cog4KDHeLa cells. In contrast,
the proportions of MGAT5 in the third cisterna and GalT in the
fourth cisterna were reduced upon Cog4KO, indicating a shift
of these enzymes toward the cis side of the Golgi (Figure 4F).
This suggests that the overall loss of enzyme levels is largely
due to loss in the trans-Golgi. Confocal microscopy showed
increased colocalization between cis-Golgi marker GM130 and
exogenously expressed GalT-YFP in the Cog4KO cells (Figures
4G and 4H), a finding also reported in the literature (Climer
et al., 2018).
It was puzzling that neither the level nor the localization of
FUT8 was altered in the Cog4KO model. The action of FUT8
was investigated on flux maps showing all reactions needed
for generating the computed glycan profiles of WT and Cog4KO
HEK293T cells. The FUT8-catalyzed reactions with the highest
proportion of flux (i.e., the most prominent fucosylation steps)
cluster away from the most abundant fucosylated glycans
(compare blue and red dots in Figure 5A and Figure S4).
The main fucosylation reactions occur early during complex
N-glycan processing, while the most abundant fucosylated gly-
cans are mature complex glycans (Figure 5A; Figure S4). We
therefore compared the fluxes of the reactions competing with
the top six FUT8 reactions between WT and Cog4KO cells
(Figure 5B; Table 1). After weighting these fluxes using the total
fucosylation flux in the given cell line, the Cog4KO cell line
showed more preference to fucosylate Hex4HexNAc4 than WT
due to less competition by GalT and MGAT5. Overall, the
weighted ratios between the two sets of fluxes suggest that
the observed decrease in total fucosylation is due to a lower total
amount of complex N-glycans. However, when comparing WT
and knockout (KO) cells, flux distributions are altered in ways
that do not always lend themselves to simplistic explanation.
For example, Hex3HexNAc4 is galactosylated more in KO cells
at the expense of branching by MGAT5. In contrast, galactosyla-
tion of Hex4HexNAc4 is reduced in KO cells due to sialyltransfer-
ase (SiaT) and FUT8, which become dominant over GalT for the
Hex4HexNAc4 substrate. Thus, our model is able to predict unin-
tuitive changes in enzyme homeostasis and fluxes through
glycan processing reactions.
Previous work combining computational simulations of the
N-glycosylation reaction network and in vitro experiments in Chi-
nese hamster ovary (CHO) cells has shown that the suppression
of GalT can lead to the formation of higher amounts of tri- and
tetra-antennary glycans (McDonald et al., 2014). We sought to
Figure 4. Predicting Organizational Changes in Trafficking Defective Cell Lines
(A and B) Observed and simulated glycan profiles of Cog4KD HeLa cell lines (A) and Cog4KO HEK293T cell lines (B). Error bars for glycan profiling are SEM
for n = 3.
(C) Total effective enzymatic rate changes predicted by the model following fitting as a result of Cog4 perturbation. The x axis is on a log scale. Error bars for total
effective enzymatic rates and distributions are SD for n = 20 (Cog4KD HeLa) and n = 21 (Cog4KO HEK293T) individual fitting procedures.
(D)Western blot analysis of endogenousMGAT1, GalT, and FUT8 and quantification normalized toWTHEK293T. Error bars for western blot quantification are SD
for n = 3. ns, not significant; *p < 0.05 for a Student’s t test.
(E) Predicted relative distribution of MAN1 following the fitting of WT and Cog4KD HeLa glycan profiles.
(F) Predicted relative distributions of selected enzymes in WT and Cog4KO HEK293T cells in each cisterna normalized to the total predicted effective enzymatic
rate for each enzyme for each cell line.
(G) Airyscan confocal microscopy of GM130 and exogenous GalT-YFP in nocodazole-treated WT and Cog4KO HEK293T cell lines.
(H) Pearson’s correlation coefficient for WT and Cog4KO HEK293T cells. Pearson’s correlation coefficients were calculated for each Golgi stack, and error bars
are SD for n = 4 cells with 151 (WT) and 131 (Cog4KO) stacks. ***p < 0.001 for a Student’s t test.
See also Figures S3 and S6 and Table S3.
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test whether this effect is also produced using our stochastic
model of glycosylation in WT and Cog4KO HEK293T cells. In
agreement with previous work (McDonald et al., 2014), varying
the effective enzymatic activity of only GalT can control glycan
branching. Increasing GalT activity decreased the abundance
of both tri- and tetra-antennary glycans as reported (Figures
5C and 5D) (McDonald et al., 2014). The maximum relative abun-
dance of highly branched glycans that could be reached at low
GalT activities was considerably lower for the Cog4KO cells
compared to WT cells.
MSCs
Glycosylation has been shown to affect MSC differentiation
potential (Wilson et al., 2018). To investigate the changes in
N-glycan biosynthesis during differentiation, we modeled glycan
profiles of Y101MSCs and their derived osteoblasts. To serve as
a starting point for fitting of the osteoblast profile, the glycan pro-
file of Y101 MSCs was modeled (Figure 6A; Table S6), starting
with the WT HEK293T parameters. Due to the used scoring
system’s reliance on the square of the difference between the
simulated and the observed relative glycan abundance, it was
possible to improve the fit by manually changing enzyme param-
eters without altering the overall score. Such manual fine-tuning,
which was used for the final fitting of the Y101 MSC model,
avoided the need to introduce multiple scoring systems with
different sensitivities to different features of themodel. We stress
that manual fine-tuning of the parameters was only undertaken
when we did not wish to directly compare the two cell line
models (e.g., WT HEK293T to Y101 MSCs).
The glycan profile of osteoblasts (Wilson et al., 2016) was then
fitted (Figure 6B; Table S7) starting from the Y101 MSCmodel to
reveal changes to the glycosylation machinery that occur during
osteogenic differentiation. Osteogenic differentiation results in
an increased complex-to-oligomannose glycan ratio, causing
the model to reduce the rate of OM quenching. The recycling
of ER glycoproteins was not expected to decrease significantly
during osteogenesis. This would suggest decreased lysosomal
content in osteoblasts compared to MSCs, yet we found the
opposite (Figure S5) (Nabavi et al., 2008; Taniguchi et al.,
2010). The increased amount of complex glycan observed
upon osteogenesis is the main cause for the reduced OM
quench effective rate. However, this shift to more complex
glycans could be due to the differentiating cells cumulatively
laying down the complex N-glycan-containing extracellular
matrix while turning over intracellular (including lysosomal and
ER) glycoproteins. Hence, we focused on predictions of the
model pertaining to complex glycans only. MGAT5 levels are
predicted to decrease and move away from medial cisternae in
Figure 5. Investigating Glycan Flux in HEK293T Cells
(A) Total flux map for all enzymatic glycan processing reactions for 10,000 input glycans occurring during the simulation of the WT HEK293T glycan profile. Blue
dots represent the substrates of the six reactions with the highest fluxes of all FUT8-catalyzed reactions. Red dots represent the most abundant fucosylated
glycans in the observed glycan profile of these cells.
(B) Weighted ratio of the Cog4KO flux to the WT flux for the top six substrates for FUT8. Red arrows highlight the fluxes of the FUT8 enzyme. Arrow thickness
denotes the ratio of flux for Cog4KO and WT HEK293T cells divided by the ratio of the total core fucosylation flux for Cog4KO and WT HEK293T cells.
(C and D) Simulated relative percent abundance of tri-antennary glycans (C) and tetra-antennary glycans (D) as it varies with the total effective enzymatic rate of
GalT in WT (black squares) and Cog4KO (gray circles) HEK293T cells. The percent total effective enzymatic rate of GalT is plotted on a log scale.
See also Figure S4.
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osteoblasts (Figures 6C and 6D). This correlates with a notice-
able shift from tri- to bi-antennary glycans in osteoblasts
compared to MSCs. Altered branching affects galectin binding
(Demetriou et al., 2001). Galectins in turn have been shown to
prevent the differentiation of pre-osteoblasts (Nakajima et al.,
2014). We hypothesized that a similar mechanism could operate
earlier than the pre-osteoblast stage in the differentiation pro-
cess, because inhibiting complex glycan formation was shown
to enhance the initial commitment of MSCs to osteogenic differ-
entiation (Wilson et al., 2018). Inhibiting galectin binding with
lactose during the first 7 days of a 21-day osteogenesis program
increased osteogenic differentiation (Figures 6E and 6F). This
implies that the reduction in N-glycan antenna number, which
is observed in osteoblasts and predicted to be a consequence
of alteredMGAT5 levels and localizations, is a contributing factor
in osteogenic differentiation.
DISCUSSION
This work has generated a computational model of Golgi-based
N-glycan processing through iteration of computation and ex-
periments. By using our in silico methodology to reproduce the
qualitative features, as well as to create high-quality quantitative
fits for glycan profiles, we can predict alterations in the enzyme
organization of cell lines that result from disruptions to the Golgi
trafficking machinery (Bailey Blackburn et al., 2016).
Nonetheless, modeling needs to be seen as a process of dis-
covery, rather than simply an end result. As the cycles of iterative
modeling progressed from HeLa cells to describe the more intri-
cate HEK293T and MSC glycan profiles, it became clear that
substrate specificity needed to be included for several enzymes.
Our fitting suggested the profiles were particularly sensitive to
GalT and SiaT, so substrate specificity was selectively intro-
duced by applying scaling factors that are consistent with the
substrate specificities of enzymes reported in the literature
(Barb et al., 2009; Joziasse et al., 1987; Ramasamy et al.,
2005). Our results also suggest that variable substrate specificity
could be particularly relevant for hybrid glycans that were often
poorly modeled when compared with complex glycans. Only a
small number of differences were found between cell surface
proteomes of WT and those of Cog4KO HEK293T cells (Fig-
ure S6), suggesting that alterations in the glycan profile due to
site-specific glycosylation (Losfeld et al., 2017) are likely to be
limited. However, we cannot eliminate the influence of site-
specific glycosylation on changes in the osteoblast glycan
profile. To improve the accuracy of modeling in the future, the
variability in the half-lives of subsets of glycoproteins could
also be considered.
Our primary goal in developing our modeling technique was to
understand the perturbations of the glycosylation enzymes
caused by defects in theCOGcomplex. Defects in this trafficking
complex cause several CDGs by altering the recycling, and
consequently the levels and localizations, of glycosylation en-
zymes (Oka et al., 2004; Steet and Kornfeld, 2006). For the com-
parison of cell lines with a disrupted COG complex (e.g., WT
HEK293T versus Cog4KO HEK293), we made the assumption
that the enzymatic rate constants do not change between the
cell lines we compared. This is because disruption to the COG
complex alters enzyme sorting, not the physical state of the
enzyme. Therefore, in these COG mutant cases, predictions of
the changes in enzyme activity parameters represent changes
in the amount of enzyme available within specific cisternae.
This is the main prediction on which we have focused our
validations.
Our model provides an excellent tool to predict all alterations
to the effective enzymatic rates of the glycosylation enzymes
and their localizations, and thereby shed light on glycan biosyn-
thetic details in Golgi trafficking-defective cell lines.Modeling the
Cog4KD HeLa cell profile has led us to predict a shift in the trans
direction of the MAN1 enzyme. Because complex glycan levels
are low, we can only make confident predictions regarding the
enzymes acting on oligomannose glycans in this system. In
contrast, modeling the glycan profile of Cog4KO HEK293T cells
predicted shifts in the levels and/or localizations of several en-
zymes acting on complex glycans. This included decreased
levels and a shift toward the cis-Golgi for GalT and MGAT5 as
a result of Cog4KO. Other enzyme levels, such as those of
FUT8, are predicted to be less sensitive to Cog4KO, and several
of these predictions, including the altered GalT localization,
agree with previous reports (Climer et al., 2018) and/or were vali-
dated experimentally.
Themodel allowedus togeneratefluxmapsdescribing thevari-
ation in glycan biosynthetic pathways as a consequence of the
mutation. This information highlights which reactions could be
best targeted to correct the glycan profile of a patient or to
glyco-engineer recombinant therapeutic proteins. For example,
by isolating the most abundant fucosylation reactions in silico,
we found that Hex4HexNAc4 was a more favorable substrate for
Table 1. WT and Cog4 KO Fluxes
Glycan Source
Normalized
KO/WT Glycan Target Enzyme
Hex3HexNAc3 0.83 Fuc1Hex3HexNAc3 FUT8
Hex3HexNAc3 0.67 Hex3HexNAc4 MGAT2
Hex3HexNAc4 0.79 Hex4HexNAc4 GalT
Hex3HexNAc4 0.81 Fuc1Hex3HexNAc4 FUT8
Hex3HexNAc4 0.37 Hex3HexNAc5 MGAT5
Hex3HexNAc5 0.49 Fuc1Hex3HexNAc5 FUT8
Hex3HexNAc5 0.17 Hex4HexNAc5 GalT
Hex4HexNAc4 0.82 Hex5HexNAc4 GalT
Hex4HexNAc4 1.53 Fuc1Hex4HexNAc4 FUT8
Hex4HexNAc4 2.64 NeuAc1Hex4HexNAc4 SiaT
Hex4HexNAc4 0.31 Hex4HexNAc5 MGAT5
Hex5HexNAc3 0.97 Fuc1Hex5HexNAc3 FUT8
Hex5HexNAc3 0.71 Hex3HexNAc3 MAN2
Hex5HexNAc4 0.60 Fuc1Hex5HexNAc4 FUT8
Hex5HexNAc4 0.61 NeuAc1Hex5HexNAc4 SiaT
Normalized flux between glycan substrate and glycan product. The
normalization is calculated by taking the ratio of flux between each sub-
strate and product for Cog4KO andWTHEK293T cells andmultiplying by
the ratio of the total core fucosylation flux for Cog4KO and WT HEK293T
cells. Normalized KO/WT fluxes over 1.0 reflect a preference for this
pathway in the Cog4KO HEK293T cell line, and vice versa.
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FUT8 in the Cog4KO cells than inWT. This was a consequence of
less competition from GalT and MGAT5 for this substrate. Thus,
although decreased fucosylation flux in the Cog4KO cells is due
to lower complex glycan levels (a consequence of reduced
MGAT1), simple overexpression of MGAT1 would result in
increased fucosylation but with an altered profile compared to
WT. Thismakes ourmodel a potentially powerful tool in the devel-
opment of treatments for COG-CDGs (Wu et al., 2004).
We also used our modeling methodology to predict adaptions
of the glycosylation machinery during the differentiation of MSCs
into osteoblasts. We observed an MGAT5-mediated shift from
tri- to bi-antennary glycans upon differentiation. The degree of
N-glycan branching has been linked to receptor endocytosis
that affects cell proliferation and differentiation (Lau et al.,
2007) via galectin binding (Demetriou et al., 2001). Inhibition of
galectin binding by lactose promoted osteogenesis even earlier
during differentiation in our hands than previously reported (Na-
kajima et al., 2014). Lactose was effective in the first week of the
3-week process. This is similar in timing to kifunensine, a drug
that abrogates complex branching, and promoted differentiation
Figure 6. Predicting Alterations in Glycan Processing as a Result of Osteogenesis
(A and B) Observed and simulated glycan profiles of MSCs (A) and MSCs following 21-day osteogenic differentiation (B).
(C) Total effective enzymatic rate changes predicted to occur upon differentiation derived following fitting of the osteoblast glycan profile. The x axis is shown on a
log scale.
(D) Distribution of MGAT5 in the Golgi stack, as predicted by the fitting of Y101MSC and osteoblast glycan profiles. Error bars for glycan profiling are SEM for n =
3. Error bars for total effective enzymatic rates and distributions are SD for n = 14 (MSC) and n = 20 (osteoblast) individual fitting runs.
(E) Representative alizarin red-stained Y101 MSCs following 21-day osteogenic differentiation in the presence of either sucrose or lactose during the first 7 days.
(F) Quantification of the eluted alizarin red stain for n = 10. ***p < 0.001.
See also Figure S5 and Tables S6 and S7.
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within the first week (Wilson et al., 2018). This suggests that a
switch from tri- to bi-antennary glycans releases an inhibitory ef-
fect on differentiation, likely by promoting the endocytosis of a
key receptor or receptors (Lau et al., 2007).
In summary, we have developed a computational workflow to
predict the architecture of the glycan biosynthetic machinery in
the Golgi based on an SSA and an approximate Bayesian
computation (ABC) fitting algorithm. Although other fitting meth-
odologies, such as genetic algorithms (Liu et al., 2008), a non-
linear least-squares (Marquardt-Levenberg) method (Krambeck
et al., 2017), and maximum likelihood estimation (Sou et al.,
2017), have been used in glycosylation modeling, our use of a
Bayesian fitting approach allows us to use prior knowledge of
the system to suggest solutions most compatible with both
data and existing knowledge. Through the use of Bayesian
fitting, we can make comparisons between cell lines in a high-
dimensional parameter space with uncertain quality of informa-
tion. This enables us to make progress, especially when under-
standing changes among biological settings. We show that our
methodology is capable of generating accurate and testable
hypotheses regarding enzyme levels and localizations by simu-
lating the glycan profiles of human cell lines perturbed through
drug treatments, genetic manipulation, and even a process
as complex as differentiation. Applying our approach to Golgi
trafficking-defective cell lines allowed us to predict which en-
zymes may be sensitive to Cog4KO, thus presenting an in silico
approach to the experimental identification of COG-sensitive
Golgi proteins (Oka et al., 2004). The ability to predict alterations
to Golgi enzymes, as well as to probe in silico-generated flux
maps to identify changes in glycosylation pathways, has
possible applications in the understanding and treatment of
COG-CDGs and the potential to be used in the glyco-engineer-
ing of biologics.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cog4KDHeLa cells were generated by the Ungar group by stable transfection of a Cog4 shRNA plasmid (Abdul Rahman et al., 2014).
HEK293T cells andCog4KOHEK293T cells were a kind gift fromVladimir Lupashin (Bailey Blackburn et al., 2016). Y101MSCswere a
kind gift from Paul Genever (James et al., 2015).
METHOD DETAILS
Cell culture and osteogenic differentiation
Cells were grown in Dulbecco’s modified essential medium (DMEM) (Life Technologies) in the presence of glutamax, penicillin/strep-
tomycin and 10% fetal bovine serum (basal medium). Cells were incubated and grown at 37C with 5% CO2. Cells were passaged
when reaching 90% confluency by resuspension (HEK293T) or trypsinization (HeLa cells and MSCs).
For osteogenic differentiation, 80,000 MSCs were seeded in wells of a 24-well dish. Following overnight incubation, the medium
was replaced with osteogenic medium (basal medium supplemented with L-ascorbic acid-2-phosphate (50 mg/mL), b-glycero-
phosphate (5 mM) and dexamethasone (10 nM)). Cells were grown for 21 days with medium changes every 3-4 days with oste-
ogenic medium. For the conditions requiring treatment with lactose (100 mM) or sucrose (100 mM) medium was changed every
day for the first 7 days of osteogenesis and from then on, the cells were grown in osteogenic medium with medium changes every
3-4 days up to day 21.
Modeling framework
Linear notation
In order to perform string substitutions in silico, the complex structures of N-glycans needed to be represented in a form of linear
notation. Such an approach has been taken in previous work modeling N-glycosylation (Krambeck and Betenbaugh, 2005). Taking
the oligomannose glycanMan5GlcNAc2 and the complex glycan NeuAc1Gal2GlcNAc2Man3GlcNAc2 as examples, our linear notation
would represent these glycan as:
GlcNAc4.1GlcNAc4.1Man(3.1Man:)_m6.1Man(3.1Man:)_m6.1Man:@
GlcNAc4.1GlcNAc4.1Man(3.1Man2.1GlcNAc4.1Gal:)_m6.1Man2.1GlcNAc4.1Gal6.2Sia:@
In this example the linkage between residues is denoted by the numbers in a conventional manner. Residues enclosed in brackets
represent separate branches within theN-glycan. The underscore and lowercase letters represent the continuation from the previous
residue not enclosed within the brackets. The ‘‘’’: represents the termination of the branch and the ‘‘@’’ denotes the end of the N-
glycan string. We emphasize that this notation was adopted for computational reasons and should not be seen as an attempt to
create alternative glycan nomenclature or ontology.
Stochastic simulation algorithm
Enzymes necessary for the biosynthesis of the observed N-glycans were used to simulate the glycan profile, in addition to the pro-
portion of GlcNAc2Man8, GlcNAc2Man9, GlcNAc2Man9Glc entering the Golgi apparatus and the time spent in each cisterna. For the
HeLa cell modeling, this equated to 11 enzymes in three cisternae as the effective rate of each enzyme in each cisterna was repre-
sented by a separate parameter. Enzyme competition was implicitly simulated but glycan substrate competition was not, as the pro-
cessing of the precursor glycans occurred one at a time but with all enzymes present. This was repeated for 10,000 glycans in order to
generate a simulated glycan profile. Each glycan is represented using a form of linear notation and reactions are represented by string
substitution.
Glycan profiles were simulated using an SSA (Figure 1B) based on the Gillespie, or Gillespie-Doeb, algorithm (Doob, 1945; Gilles-
pie, 1976). For two competing enzymes (E1 and E2) the total rate is the sumof the two individual rate equations. A brief summary of this
methodology for a two-reaction system is as follows. For two reactions
A+E1/
k1
B+E1
A+E2/
k2
C+E2;
we can calculate a propensity, ri for each reaction, defined by
r1 = k1½A½E1
r2 = k2½A½E2;
As well as a total propensity, R,
R= k1½A½E1+ k2½A½E2:
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An event in the time period t to t+dt is determined by drawing randomly from an exponential distribution with the total rate as itsmean.
The probability P of this event being a given reaction occurring is then calculated by computing the probabilities:
pi =
ri
R
;
with
p1 +p2 = 1:
The time interval dt is then drawn from an exponential distribution.
Approximate Bayesian computation without likelihood (cf. Figure S1)
To initially parameterise the model for Bayesian fitting of the HeLa cell glycan profile we had to construct prior distributions for each
rate parameter. The total effective enzymatic rate was divided over the different cisternae, based on the enzymes’ proposed
localization e.g., 80% of the effective enzymatic rate of SiaT was placed in the third cisterna. 80% of the input glycan was
GlcNAc2Man8 and the time in each cisterna was 10 minutes. The shapes of the prior distributions for each enzyme parameter
were constructed as log-normal distributions if the enzyme was predominantly in that cisterna or exponential decay if not. Values
from the prior distributions were used to generate a simulated glycan profile using the methodology described above. The similarity
between the simulated and observed glycan profiles was quantified through a scoring system. The scoring system is defined by:
score=
Xn
i = 1
ðsemi  ðjobsi  simi j ÞÞ
2
If:
jobsi  simi j < semi
score= 0
Where semi is the standard error of the mean for the observed glycan i, obsi and simi are the relative abundances of glycan i in the
observed and simulated dataset respectively.
The prior distributions were sampled and the score reduced by 10% if the acceptance rate of parameter values was greater than
7% (Sherlock et al., 2015). The score was lowered until it reached a user defined threshold at which point the algorithm sampled in
that region until 10,000 parameter values for each variable had been accepted. Accepted parameter values were used to construct
the posterior distribution. This methodology is equivalent to the acceptance barriers in, for example (Toni and Stumpf, 2010).
Following fitting, the mean parameter values from < 10 individual fitting runs were used to generate simulated glycan profiles.
Glycans produced at a relative abundance under 0.1% were removed. Although glycan isoforms can be distinguished within the
model, isoforms were collated together to generate one value. Computational simulations were run in parallel on the York Advanced
Research Computing Cluster. To assess convergence of multiple Markov chains, the Gelman-Rubin R-Statistic was used (Gelman
and Rubin, 1992) and the chains visually assessed to confirm they did accumulate close to the bounds of the prior distribution. The
Gelman-Rubin statistic compares the in-chain variance with the between-chain variance providing assurance that the posterior
distribution has been explored to a satisfactory extent. For model development with the HeLa and HEK293T cell line data, the
oligomannose distribution was modeled initially in isolation before combining the fitting with complex and hybrid glycans.
Once a threshold was reached, the posterior distributions were assessed against the prior distributions. We are conscious that in
our method we have no means to access biological rate constants directly. Hypothetically, this could be achieved by assessing
mRNA expression, however, this does not necessarily give a reliable estimation of protein levels. In addition, while enzymatic
procession rates are based on reported measured values, these are typically from in vitro, not in vivomeasurements. To avoid large
amounts of time evaluating space in the tails of prior distributions in a high dimensional parameter space, we permitted ourselves to
move prior distributions between fitting runs where there was reasonable biological and numerical evidence to do so. A Mann-
Whitney U test was used to assign significance in means between the prior and posterior distributions for each parameter. Only if
the change in means was found to be significant was the prior distribution for that parameter altered, and the rejection algorithm
run again to a lower threshold. This is a statement of our lack of certainty regarding the composition of the prior distribution due
to the absence of direct measurements for the desired rates, and our need to avoid prior distributions that are flat, or nearly flat,
due to that large parameter space we are operating in.
Confocal Microscopy
WT and Cog4KO HEK293T cells were transfected with GalT-YFP (Cottam et al., 2014) using Xfect (Clontech) following the manufac-
turer’s instructions. 24 hours post-transfection 60,000 cells were seeded on poly-lysine-treated glass coverslips in a 24-well dish.
45 hours after transfection cells were treated with nocodazole (5 mM) for 3 hours. After nocodazole treatment the cells were washed
with PBS and then fixed in 4% paraformaldehyde (Thermo Scientific) for 15 minutes. Cells were then washed with PBS, then glycine
(20 mM glycine in PBS) and then incubated in blocking solution (2%BSA, 0.1% saponin, 20 mM glycine in PBS) for 30 minutes. Cells
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were stained as indicated with anti-GM130-Alexa647 (1/400, BD Biosciences), anti-MAN1 (1/100, Thermo), anti-endo-mannosidase
(1/100, Abnova) for 1 hour before being washed in blocking solution and mounted (Immunomount, Genetex) onto slides. Slides were
imaged on a Zeiss LSM 880 operating in Airyscan mode with a 633 oil objective. Pearson’s correlation coefficients were calculated
for each individual Golgi stack and averaged for each cell analyzed. Images were analyzed using ImageJ.
Alizarin red staining
Cells were first gently washed with PBS before fixation in 4% formaldehyde (Kautex) for 20 minutes. Formaldehyde was then
removed with three PBS washes prior to incubation with Alizarin Red S (40 mM, pH 4.2) for 20 minutes at room temperature. Cells
were thenwashed three timeswith PBS followed by excessive washes with tap water. Images were acquired on a stereomicroscope
fitted with an AxiocamMrC5 (Zeiss). After drying, the alizarin red stain was eluted into 200 mL 10% cetylpyridinium chloride for 1 hour
while shaking at room temperature. The supernatant was transferred into a 96-well plate and the absorbance read at 570 nm with a
microplate spectrophotometer (Multiskan G0, Thermo).
Western blotting
Cells from a 6-well plate at 90% confluency were gently washed twice with PBS before 200 mL of SDS-PAGE buffer (5% glycerol,
50 mM Tris pH 6.8, 50 mM DTT, 1% SDS, 0.74 mM bromophenol blue) was added to each well and incubated at 20C for 5 minutes.
Samples were then transferred into a microcentrifuge tube and heated at 95C for 5 minutes before storage at 20C.
Aliquots of lysate samples (10-20 mL) were loaded into an SDS-PAGE gel and run at 100 V through the stacking gel and then 180 V
through the separating gel until adequate separation of the pre-stained ladder (All Blue, Bio-Rad) had occurred. Proteins were trans-
ferred onto a polyvinylidene fluoride membrane (Immun-blot, Bio-Rad) by semi-dry transfer. Following transfer, the membrane was
blocked in 5%milk powder in PBSwith 0.05% tween-20 for 1 hour. Primary antibodies were incubated with themembrane overnight
in blocking buffer at 4C. Primary antibodies used in this study were anti-LAMP1 (1/100, gift from Paul Pryor, University of York),
anti-GalT (1/500, R&D Systems, AF3609), anti-MGAT1 (1/500, Abcam, ab180578), anti-FUT8 (1/1000, Abcam, ab191571) and
anti-GAPDH (1/500,000, Applied Biosystems). The membrane was washed four times with the blocking buffer before incubation
at 20C for 1 hour with HRP conjugated secondary antibody diluted in blocking buffer. The membrane was then washed a further
three times with the blocking buffer and then two times with PBS containing 0.05% tween-20. The membrane was imaged on a
Syngene GeneGenius system following exposure to BM Chemiluminescence Western Blotting Substrate (Roche) and densitometry
carried out with ImageJ. Glycosylation enzyme bands were normalized to the levels of GAPDH. TheWT andCog4KO band intensities
were quantified from the same membrane.
N-glycan release
All glycan profiling data have been previously publishedwith the exception of those from the swainsonine-treated HEK293T cells. The
use of MALDI-MS for the analysis of permethylated glycans as applied here has been demonstrated to provide reliable relative
quantification (Wada et al., 2007). HEK293T cells were treated with swainsonine (Cayman Chemicals) at 10 mg/mL for 48 hours prior
to harvesting for glycan analysis. At90%confluency cells were washed five timeswith PBS and harvested by scraping into amicro-
centrifuge tube and then centrifuged at 14000 g for 5 minutes at 4C. The supernatant was removed and lysis buffer (4% (w/v) SDS,
100 mM Tris/HCl pH 7.6, 0.1 M DTT) was added at ten times the pellet volume. The sample was incubated at 97C for 5 minutes and
centrifuged at 14000 g for 10 minutes. The supernatant was then stored at 80C.
The thawed supernatant was diluted tenfold in urea solution (8 M urea in 100 mM Tris/HCl pH 8.5) and centrifuged in an ultrafiltra-
tion tube (Amicon Ultra-0.5, Ultracel-30 membrane, nominal mass cutoff 30 kDa, Millipore) in 400 mL increments at 15000 g for 10 mi-
nutes each until the complete sample passed through the filter. The membrane filter was washed with the urea solution three times,
before the addition of iodoacetamide solution (40 mM in 300 mL urea solution). The sample was incubated in the dark for 15 minutes
and then centrifuged at 14000 g for 10 minutes. Following this the sample was washed with urea solution once followed by ammo-
nium bicarbonate (300 mL, 50 mM pH 8) three times. The membrane filter was incubated at 37C for 16 hours with 8 U of PNGase F in
100 mL ammonium bicarbonate (50 mM) solution. Released glycans were then eluted into a fresh collection tube by centrifugation of
the ammonium bicarbonate and an additional spin with 100 mL water (HPLC grade).
Permethylation
The elutedN-glycans were transferred to glass tubes and dried in a vacuum concentrator. The sample was twice washedwith 100 mL
water (HPLC grade) and dried each time. 20 drops of dimethyl-sulfoxide (DMSO) followed by two heaped microspatulas of finely
ground sodium hydroxide pellets were then added to the dried glycans. Iodomethane was then added to the sample as follows:
10 drops followed by 10 minute incubation; 10 drops followed by 10 minute incubation; 20 drops followed by 20 minute incubation.
Sodium thiosulfate (1 mL, 100 mg/mL) and dichloromethane (1 mL) were then immediately added to the sample. The organic and
aqueous phases were mixed by vortexing and then allowed to separate. The aqueous layer was removed and the organic layer
was washed with a similar volume of water (HPLC grade) three or four times. The organic layer was then dried in a vacuum
concentrator.
Cell Reports 27, 1231–1243.e1–e6, April 23, 2019 e4
Glycan mass spectrometry
Permethylated glycan sampleswere redissolved in 20 mL ofmethanol, and the glycan solutionwasmixed in a 1:1:0.5 ratio with 20mg/
mL 2,5-dihydroxybenzoic acid (DHB) in 70%methanol and sodium nitrate (0.5M). 2 mL of this mixture was then spotted onto aMALDI
target plate and allowed to air dry. Mass spectra were acquired on a 9.4 T SolariX FT-ICR mass spectrometer (Bruker Daltonics)
recorded over the m/z range 400-4000 in positive ion mode with 500 laser shots. 8 scans were averaged, and the laser power
was set between 30 and 60%. Spectra were calibrated externally using Bruker Peptide Mix II.
Crude membrane proteomics
Cells were grown to near confluency in a 10 cm tissue culture dish before being harvested by centrifugation at 800 3 g for three
minutes at room temperature. The resulting pellet was then washed twice with PBS and then twice in ice cold permeabilization buffer
(20 mM HEPES pH 7.4, 150 mM potassium acetate, 5 mM magnesium acetate, 5 mM DTT), before incubation in digitonin solution
(0.1% digitonin in permeabilization buffer) at 4C with rotation for 30 minutes. Subsequently the total cell membrane fraction was
pelleted by centrifugation at 800 3 g, 4C. The membrane pellet was then resuspended in urea lysis buffer (20 mM HEPES pH
8.0, 9 M urea, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate and 1 mM b-glycerophosphate) and lysed with a sonic
probe, before clearing the lysate through centrifugation at 20,000 3 g for 15 minutes and transferring the supernatant into a LoBind
microcentrifuge tube (Eppendorf).
Proteins were reduced with 5 mMdithiothreitol and incubation at 55C for 30mins before alkylating with 15 mM iodoacetamide for
30 min at room temperature. Solutions were diluted to 2 M urea with aqueous 50 mM ammonium bicarbonate before digesting with
the addition of 1mg of trypsin/Lys-C proteasemixture (Promega) and incubation at 37C. Digestion was stopped after 16 hwith addi-
tion of trifluoroacetic acid (TFA) to 0.1% (v:v). Peptides were desalted using Strata 50 mg C18 cartridges (Phenomenex). Cartridges
were prepared by passing through 3 mL acetonitrile, 2 mL aqueous 80% (v:v) acetonitrile 0.1% (v:v) TFA and 2 mL aqueous 0.1%
(v:v) TFA. Peptideswere loaded and cartridgeswashedwith 23 0.25 mL aqueous 0.1% (v:v) TFA. Peptideswere elutedwith aqueous
80% (v:v) acetonitrile 0.1% (v:v) TFA before drying in a vacuumconcentrator and reconstituting in aqueous 0.1% (v:v) TFA. A common
sample pool was created by taking equal aliquots of all samples.
Samples were loaded onto an UltiMate 3000 RSLCnano HPLC system (Thermo) equipped with a PepMap 100 A˚ C18, 5 mm trap
column (300 mm x 5 mm Thermo) and a PepMap, 2 mm, 100 A˚, C18 EasyNano nanocapillary column (75 mm x 500 mm, Thermo). The
trap wash solvent was aqueous 0.05% (v:v) trifluoroacetic acid and the trapping flow rate was 15 mL/min. The trap was washed for
3 min before switching flow to the capillary column. Separation used gradient elution of two solvents: solvent A, aqueous 1% (v:v)
formic acid; solvent B, aqueous 80% (v:v) acetonitrile containing 1% (v:v) formic acid. The flow rate for the capillary column was
300 nL/min and the column temperature was 40C. The linear multi-step gradient profile was: 3%–10% B over 8 mins, 10%–35%
B over 115 mins, 35%–65% B over 30 mins, 65%–99% B over 7 mins and then proceeded to wash with 99% solvent B for 4 min.
The column was returned to initial conditions and re-equilibrated for 15 min before subsequent injections.
The nanoLC system was interfaced with an Orbitrap Fusion hybrid mass spectrometer (Thermo) with an EasyNano ionisation
source (Thermo). Positive ESI-MS and MS2 spectra were acquired using Xcalibur software (version 4.0, Thermo). Instrument source
settings were: ion spray voltage, 1,900 V; sweep gas, 0 Arb; ion transfer tube temperature; 275C. MS1 spectra were acquired in the
Orbitrap with: 120,000 resolution, scan range: m/z 375-1,500; AGC target, 4e5; max fill time, 100 ms. Data-dependent acquisition
was performed in top speed mode using a fixed 1 s cycle, selecting the most intense precursors with charge states 2-5. Easy-IC
was used for internal calibration. Dynamic exclusion was performed for 50 s post precursor selection and a minimum threshold
for fragmentation was set at 5e3. MS2 spectra were acquired in the linear ion trap with: scan rate, turbo; quadrupole isolation, 1.6
m/z; activation type, HCD; activation energy: 32%; AGC target, 5e3; first mass, 110 m/z; max fill time, 100 ms. Acquisitions were
arranged by Xcalibur to inject ions for all available parallelizable time.
Peak lists in .raw format were imported into Progenesis QI (Version 2.2., Waters) and LC-MS runs aligned to the common sample
pool. Precursor ion intensities were normalized against total intensity for each acquisition. A combined peak list was exported in .mgf
format for database searching against the human subset of the UniProt database. Mascot Daemon (version 2.6.1, Matrix Science)
was used to submit the search to a locally-running copy of the Mascot program (Matrix Science Ltd., version 2.6.1). Search criteria
specified: Enzyme, trypsin; Max missed cleavages, 2; Fixed modifications, carbamidomethyl (C); Variable modifications, oxidation
(M); Peptide tolerance, 3 ppm; MS/MS tolerance, 0.5 Da; Instrument, ESI-TRAP. Peptide identifications were passed through the
percolator algorithm to achieve a 1% false discovery rate and individual match filtered to require a minimum expect score of
0.05. The Mascot .XML result file was imported into Progenesis QI and peptide identifications associated with precursor peak areas.
Normalization was performed between acquisitions against total precursor intensities for a subset of known ER proteins. Relative
protein abundance was calculated using precursor ion areas from non-conflicting unique peptides. Statistical testing was performed
in Progenesis QI and ANOVA-derived p values were converted tomultiple test-corrected q-values using the Hochberg and Benjamini
approach.
Beta-hexosaminidase assay
Cells were seeded in a 24-well tissue culture plate, harvested in PBS, pelleted with centrifugation at 800 3 g, and resuspended in
citrate buffer (100 mL, 40 mM sodium citrate, 60 mM citric acid, 0.15% Triton X-100). The lysate (25 mL) was added to the bottom
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of a clear plastic tube, followed by 100 mL substrate solution (100 mM citrate buffer, pH 5.0, 0.5 mM 4-methylumbelliferyl-2-
acetamido-2-deoxy-beta-D-glucopyranoside, 0.27 M sucrose). After exactly three minutes the reaction was stopped with the
addition of 1 mL 1 M sodium carbonate. Fluorometric quantification was achieved by exciting at 360 nm wavelength and reading
emission at 445 nm.
QUANTIFICATION AND STATISTICAL ANALYSIS
Student’s t tests were used to assess significance between band intensities from western blotting and for comparison of Pearson’s
correlation coefficient. Band intensities and Pearson’s correlation coefficients are shown as mean ± standard deviation. Pearson’s
correlation coefficients were calculated using ImageJ.MannWhitney-U tests were used to determine statistical significance between
simulated parameters from independent fitting runs. P values are denoted by: ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Further details of statistical tests used can be found in the relevant figure legends.
DATA AND SOFTWARE AVAILABILITY
The software used for modeling and fitting glycan profiles can be requested by emailing Daniel Ungar (dani.ungar@york.ac.uk) or A.
Jamie Wood (jamie.wood@york.ac.uk).
The glycan profiling, imaging and western blot data have been deposited at https://doi.org/10.15124/97b5c373-e7ee-
4975-b82f-7147be59d197
The proteomics data used for Table S3 and Figure S6 have been deposited at https://doi.org/10.6019/PXD013211. The accession
number is PRIDE: PXD013211.
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